ABT 702 Dihydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524108

CAS#: 1188890-28-9

Description: ABT 702 Dihydrochloride is a potent non-nucleoside adenosine kinase inhibitor, selective over other sites of adenosine interaction like A1, A2A and A3 receptors, adenosine transporter and adenosine deaminase. It displays oral activity in animal models of pain and inflammation.


Price and Availability

Size
Price

Size
Price

Size
Price

ABT 702 Dihydrochloride, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 524108
Name: ABT 702 Dihydrochloride
CAS#: 1188890-28-9
Chemical Formula: C22H21BrCl2N6O
Exact Mass:
Molecular Weight: 536.25
Elemental Analysis: C, 49.27; H, 3.95; Br, 14.90; Cl, 13.22; N, 15.67; O, 2.98


Synonym: ABT 702 Dihydrochloride; ABT 702; ABT-702; ABT702;

IUPAC/Chemical Name: 5-(3-Bromophenyl)-7-[6-(4-morpholin​yl)-3-pyrido[2,3-d]byrimidin-4-amine dihydrochloride

InChi Key: OOXNYFKPOPJIOT-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H19BrN6O.2ClH/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29;;/h1-5,10-13H,6-9H2,(H2,24,26,27,28);2*1H

SMILES Code: BrC1=CC(C2=CC(C3=CC=C(N4CCOCC4)N=C3)=NC5=NC=NC(N)=C52)=CC=C1.[H]Cl.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Xu B, Gao L, Wang L, Tang G, He M, Yu Y, Ni X, Sun Y. Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer. 2013 Sep 3;109(5):1279-86. doi: 10.1038/bjc.2013.480. Epub 2013 Aug 15. PubMed PMID: 23949154; PubMed Central PMCID: PMC3778313.

2: Keating FK, Schneider DJ. The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. J Thromb Thrombolysis. 2009 Jul;28(1):38-45. doi: 10.1007/s11239-008-0239-5. Epub 2008 Jun 25. PubMed PMID: 18574670.

3: Bozlu G, Atici A, Turhan AH, Polat A, Nayci A, Okuyaz C, Taskinlar H. Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Brain Res. 2007 Apr 27;1143:193-8. Epub 2007 Feb 1. PubMed PMID: 17320823.

4: Reyes YA, Shimoyama T, Akamatsu H, Sunamori M. MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation. Eur J Cardiothorac Surg. 2006 Mar;29(3):304-11. Epub 2006 Jan 19. PubMed PMID: 16427299.

5: Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists. J Med Chem. 1998 Jan 1;41(1):74-95. PubMed PMID: 9438024.

6: Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. PubMed PMID: 9435164.

7: Albert DH, Tapang P, Morgan DW, Curtin ML, Sheppard GS, Davidsen SK, Summers JB, Carter GW. ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats. Inflamm Res. 1997 Aug;46 Suppl 2:S133-4. PubMed PMID: 9297547.

8: Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L, Heyman HR, Davidsen SK, Summers JB, Carter GW. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. Eur J Pharmacol. 1997 Apr 23;325(1):69-80. PubMed PMID: 9151941.